According to the report, the global bronchodilators market is majorly driven by an increasing focus on the development of monoclonal antibody therapy. Monoclonal antibody therapy is increasingly being used for the treatment of diseases such as tumour, which in turn has inspired market players to double their efforts and focus on the development of monoclonal antibody therapy. The positive results shown by monoclonal antibody therapy is expected to increase its uptake. An increasing number of people who are suffering from asthma, COPD are behind the growth of this market. Several deaths have occurred in low and middle-income nations on account of high air pollution caused by heating and cooking, outdoor pollution as well as pollution from dust and chemicals which have resulted in respiratory infections. The government is also supporting the growth of the global bronchodilators market by increasing awareness among the population in general through patient education program.
Another factor which is expected to boost the growth of this market is key drugs which are at the later stage in the pipeline from manufacturers such as AtraZeneca and Sanofi. Manufacturers in the market are developing new forms of drug administration which is expected to increase the intake of drugs and drive the global bronchodilators market. Players within the bronchodilators market are investing extensively for the development of different kinds of nebulizers and inhalers which will provide easy access to patients. Ultrasonic nebulizers which have advanced technology as compared to jet nebulizers are available in markets today. Another important factor which has favoured the global bronchodilators market is the use of electronic system technology such as electronic health records.
Bronchodilators are drugs used by people suffering with asthma. These drugs help open the airway passages. These are also used for expanding the wind pipe, thus improving the breathing of the individuals suffering from lung infections, bronchial asthma, and chronic obstructive pulmonary disease (COPD).
There are two forms of bronchodilators: short acting bronchodilators and long acting bronchodilators. The short acting bronchodilators provide quick relief from asthma and can be used on a daily basis. The long acting bronchodilators assist in controlling the symptoms of asthma by opening the air passage for up to 12 hours. Short acting bronchodilators include albuterol (a generic solution for nebulizers), metaproterenol, pirbuterol, and levalbuterol. Long acting bronchodilators include advair, symbicort, and dulera which is a combination of beta agonist bronchodilator and a steroid. Major side effects of bronchodilators include increased heart rate, muscle cramps, inappropriate sleeping pattern, upset stomach, and others. According to the Centers for Disease and Control of Infection reports published in 2014, the number of adults who were diagnosed with asthma was 17.7 million, out of which, there were 3,651 deaths due to asthma, and women were the most affected. According the World Health Organization, in 2012, more than three million people died due to COPD, which was 6% of all deaths globally.
There are three types of bronchodilator used for treating respiratory diseases: beta-agonist, anticholinergic, and theophylline. These types are available in different forms based on route of administration such as inhaler, tablet, liquid, and injectable. Inhaler is the most preferred form of administration for using beta-agonist and anticholinergic. A major disadvantage of long acting beta agonist bronchodilator is that it increases the risk of asthma death; therefore, it should be used only as an added treatment for individuals or patients who use steroid. Anticholinergics are used for treating patients suffering from COPD and asthma. Atrovent, an anticholinergic bronchodilator, is used for the treatment of COPD. It is administered using an inhaler or a nebulizer. Tiotropium bromide is a long acting anticholinergic inhaler, which is used for treating patients suffering from asthma and COPD.
The global bronchodilators market has been segmented based on form of bronchodilator, route of administration, drug class, distribution channel, and region. In terms of form of bronchodilator, the global market is divided into short acting bronchodilators and long acting bronchodilators. Based on route of administration, the market is segmented into oral, injectable, and nasal. In terms of drug class, the market is divided into adrenergic bronchodilators, anticholinergic bronchodilators, and others.
The major drivers for the growth of the global bronchodilators market are rising incidence rate of respiratory and pulmonary diseases such as asthma and COPD, growing awareness among individuals, increasing initiatives by governments and health care services, increasing demand for bronchodilator drugs, and adoption of unhealthy lifestyle. According to WHO reports, there is an increased use of tobacco among women in high-income countries and increased risk of exposure to indoor air pollutants in low-income countries. COPD affects men and women equally. The global burden of COPD was nearly 251 million cases in 2016. The WHO has designed a framework named WHO Framework Convention on Tobacco Control (WHO FCTC) to implement MPOWER package, which aims at assisting country level implementation of effective interventions focused on reducing the demand for tobacco.
Geographically, the global bronchodilators market is distributed over North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is expected to be the largest market for bronchodilators due to high incidence rate of diseases such as COPD and asthma, high demand for bronchodilator drugs, and increase in awareness. Europe holds the second largest market share. The Asia Pacific market is expected to provide a lucrative opportunity during the forecast period due to increasing disease burden, growing biopharmaceutical industry, and rising research activity along with competitive landscape in the pharmaceutical industry. The market in Latin America and Middle East & Africa is anticipated to grow owing to increasing health care infrastructure and growing public-private collaboration to expand the health care sector.
Major companies operating in the global bronchodilators market are F. Hoffmann-La Roche, Gilead Sciences, Novartis Ag, Boehringer Ingelheim, GlaxoSmithKline, Merck & Co., Inc., and AstraZeneca.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.